These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 1346801)

  • 21. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
    Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
    Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
    Estey EH; Kurzrock R; Kantarjian HM; O'Brien SM; McCredie KB; Beran M; Koller C; Keating MJ; Hirsch-Ginsberg C; Huh YO
    Blood; 1992 Feb; 79(4):882-7. PubMed ID: 1346577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New purine analogues for the treatment of chronic B-cell malignancies.
    Gribbin TE
    Henry Ford Hosp Med J; 1991; 39(2):98-102. PubMed ID: 1679757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
    Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
    Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cladribine in the treatment of chronic lymphocytic leukemia.
    Robak T
    Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
    Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.
    Hochster HS; Kim KM; Green MD; Mann RB; Neiman RS; Oken MM; Cassileth PA; Stott P; Ritch P; O'Connell MJ
    J Clin Oncol; 1992 Jan; 10(1):28-32. PubMed ID: 1727921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
    Bartlett NL; Johnson JL; Wagner-Johnston N; Ratain MJ; Peterson BA;
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):793-8. PubMed ID: 18648813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
    Pro B; Hagemeister FB; McLaughlin P; Romaguera J; Rodriguez MA; Cabanillas F; Tiongson LP; Younes A
    Leuk Lymphoma; 2006 Sep; 47(9):1818-21. PubMed ID: 17064994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
    Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-CdA in the treatment of hairy cell leukaemia.
    Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH
    J Assoc Physicians India; 2001 Aug; 49():785-7. PubMed ID: 11837464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
    Levitt MJ; Gharibo M; Strair R; Schaar D; Rubin A; Bertino JR
    J Chemother; 2009 Aug; 21(4):434-8. PubMed ID: 19622463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections.
    Juliusson G; Liliemark J
    Blood; 1992 Feb; 79(4):888-94. PubMed ID: 1346578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The purine analogs--a therapeutic beauty contest.
    Cheson BD
    J Clin Oncol; 1992 Mar; 10(3):352-5. PubMed ID: 1346799
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
    Lauria F; Rondelli D; Zinzani PL; Bocchia M; Marotta G; Salvucci M; Raspadori D; Ventura MA; Birtolo S; Forconi F; Tura S
    Leukemia; 1997 May; 11(5):629-32. PubMed ID: 9180283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases.
    Robak T; Błasińska-Morawiec M; Krykowski E; Hellmann A; Lewandowski K; Dmoszyńska A; Adamczyk-Cioch M; Kazimierczak M; Trepińska E; Dwilewicz-Trojaczek M; Kuratowska Z; Skotnicki AB; Nowak WS; Zdziarska B; Urasiński I
    Eur J Haematol; 1997 Oct; 59(4):216-20. PubMed ID: 9338619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.
    Piro LD; Carrera CJ; Beutler E; Carson DA
    Blood; 1988 Sep; 72(3):1069-73. PubMed ID: 2901280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
    Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
    J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.